Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Analyst sentiment is moderately bullish: Six firms rate Gain Therapeutics “Moderate Buy,” with five buy ratings and one sell rating. The average 12-month price target is $7.50.
• GANX opened at $2.12 and has traded between $1.51 and $4.34 over the past year. The company reported a quarterly loss of $0.11 per share, beating analysts’ expected loss of $0.14.
• Institutional investors and hedge funds own approximately 11.97% of the company, with several firms recently initiating positions, including Potomac Capital Management’s roughly $3.25 million investment.

Shares of Gain Therapeutics, Inc. (NASDAQ:GANX - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the six ratings firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $7.50.

GANX has been the subject of a number of analyst reports. Roth Capital reissued a "buy" rating on shares of Gain Therapeutics in a research report on Tuesday, May 12th. Weiss Ratings cut shares of Gain Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, June 9th. HC Wainwright reiterated a "buy" rating and issued a $8.00 target price on shares of Gain Therapeutics in a research note on Wednesday, July 1st. Oppenheimer reiterated an "outperform" rating on shares of Gain Therapeutics in a research note on Wednesday, May 27th. Finally, Wall Street Zen upgraded Gain Therapeutics from a "strong sell" rating to a "sell" rating in a report on Sunday, June 21st.

Gain Therapeutics Trading Down 1.9%

NASDAQ GANX opened at $2.12 on Friday. Gain Therapeutics has a 12 month low of $1.51 and a 12 month high of $4.34. The company has a current ratio of 4.36, a quick ratio of 4.69 and a debt-to-equity ratio of 0.02. The stock has a 50 day moving average of $1.81 and a 200-day moving average of $1.93. The company has a market cap of $92.52 million, a PE ratio of -4.24 and a beta of 0.19.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.03. On average, equities research analysts anticipate that Gain Therapeutics will post -0.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of GANX. Potomac Capital Management Inc. acquired a new position in shares of Gain Therapeutics in the fourth quarter valued at approximately $3,252,000. JPMorgan Chase & Co. bought a new position in shares of Gain Therapeutics in the third quarter worth $47,000. Apollon Wealth Management LLC bought a new position in Gain Therapeutics in the 4th quarter valued at about $64,000. Squarepoint Ops LLC acquired a new position in Gain Therapeutics during the third quarter valued at approximately $68,000. Finally, Wealthspire Advisors LLC acquired a new position in shares of Gain Therapeutics during the 4th quarter worth $54,000. Institutional investors and hedge funds own 11.97% of the company's stock.

About Gain Therapeutics

Gain Therapeutics, Inc NASDAQ: GANX is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain's lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source